# Phase 2 — Portfolio Review-Scaling Replication Checkpoint

**Status:** CERTIFIED — THREE-PRODUCT / THREE-INSURER REPLICATION COMPLETE  
**Date:** 2026-08-15

## Purpose

Close the specific empirical gap that remained after PHASE-2A: review-scaling behavior had been demonstrated on one real reviewer workload but had not yet been replicated across multiple real products and insurers.

This checkpoint does not reopen PHASE-2A, PHASE-2B, or PHASE-2C. Those gates remain certified and frozen. It consolidates their measured evidence into one narrow Phase-2 portfolio result.

## Authority and sequence

The 2026-08-15 Architecture Fitness Review authorized Phase-2 Health expansion as governed data after AFR-N1, with no architecture replacement or database migration. PHASE-2A then certified a credible path to sub-linear review scaling while explicitly declining to claim cross-product empirical proof.

PHASE-2B and PHASE-2C subsequently supplied independent real-product replication on Bajaj My Health Care and Aditya Birla Activ One.

## Comparable reviewer workloads

All three workloads use the same generic governed path:

`governed source -> canonical PDF parse -> currency candidates -> reviewer-ready groups -> MO-029 risk routing`

### Star Comprehensive

- Reviewer-ready groups: **12**
- Critical: **0**
- High: **6**
- Medium: **6**
- Low: **0**
- Expensive-review share (Critical + High): **6 / 12 = 50%**
- Product-identity-bearing production code: **0**

### Bajaj My Health Care Plan (Plan 1)

- Reviewer-ready groups: **10**
- Critical: **0**
- High: **7**
- Medium: **3**
- Low: **0**
- Expensive-review share (Critical + High): **7 / 10 = 70%**
- Product-identity-bearing production code: **0**

### Aditya Birla Activ One

- Reviewer-ready groups: **11**
- Critical: **0**
- High: **11**
- Medium: **0**
- Low: **0**
- Expensive-review share (Critical + High): **11 / 11 = 100%**
- Product-identity-bearing production code: **0**

### Aggregate

- Products: **3**
- Insurers: **3**
- Reviewer-ready groups: **33**
- Critical: **0**
- High: **24**
- Medium: **9**
- Low: **0**
- Product-identity-bearing production code introduced by normal onboarding: **0**
- Adjudication side effects: **none**
- Publication side effects: **none**

## What the replication proves

1. **Pipeline repeatability across three real insurers/products.** The same governed extraction/review/routing path operates without insurer- or product-specific runtime branches.
2. **Reusable defects can be repaired generically.** Star exposed reusable bounded-scope gaps; Bajaj exposed a reusable monetary-role precedence defect; Activ One exposed a legitimate URL-less governed-source provenance shape. Each was handled generically rather than with product-specific code.
3. **Risk is not normalized to a target metric.** The resulting expensive-review shares differ materially: 50%, 70%, and 100%. Activ One remained 100% High because its dense table/option/SI-band ambiguity is genuine under the current bounded evidence model.
4. **Fail-closed governance survives scaling pressure.** MO-029 thresholds were not weakened, unresolved structural bindings were not guessed, and routing never became adjudication or publication.
5. **Normal Health expansion remains data-driven.** The standing acceptance rule — zero product-identity-bearing production code for normal new-product onboarding — held across all three products.

## What the replication does not prove

This checkpoint does **not** claim:

- mathematically proven sub-linear human review effort as product count tends to scale;
- uniform review-cost reduction across products;
- complete Health product or concept coverage;
- complete table/row/column recovery;
- automated human adjudication;
- publication readiness of the currency candidates;
- readiness for frontend, Motor, Life, database migration, recommendations, or public launch.

The evidence instead proves that review cost is **product-structure dependent** while the architecture remains generic and fail-closed.

## Architecture interpretation

The remaining dominant expensive-review work across the portfolio is increasingly structural: table/row/column binding, sum-insured bands, option binding, and missing governing-section context.

That is useful evidence, but it is not yet sufficient reason to build a generic structural table resolver. The existing rule remains:

> Add a structural recovery capability only when future independent product pressure demonstrates a reusable failure that cannot be represented safely by the current bounded-evidence model.

A fourth product should therefore be selected for **new semantic or document-structure pressure**, not merely to increase the sample count or force a better aggregate review percentage.

## Regression evidence

Latest closure validation supplied during PHASE-2C:

- `tests/health`: **120 passed**
- `tests/factory_core`: **128 passed**
- regressions: **0**

PHASE-2A and PHASE-2B retain their separately recorded certified regression evidence.

## Certification decision

**PHASE 2 PORTFOLIO REVIEW-SCALING REPLICATION CHECKPOINT: CERTIFIED.**

The narrow Phase-2 empirical gap left by PHASE-2A is now closed: multiple real Health products across multiple insurers have exercised the same governed reviewer-workload path, reusable defects were repaired generically, materially different review-cost distributions were preserved honestly, and normal onboarding remained at zero product-identity-bearing production code.

## Next decision boundary

Do not start another product merely to repeat currency extraction. The next Health pressure case should be chosen because it exercises a materially different concept family, document structure, source-governance shape, or decision-support dependency. Existing coverage/backlog evidence should determine that choice before new implementation begins.
